Remimazolam: Is the quest for the holy grail of sedation during diagnostic or endoscopic interventions over?
- 1 December 2022
- journal article
- editorial
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 39 (12) , 909-910
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Swallowing ability and intra-oral water-retaining ability during moderate propofol sedation in healthy human volunteersEuropean Journal of Anaesthesiology, 2021
- High flow nasal oxygen during procedural sedation for cardiac implantable electronic device proceduresEuropean Journal of Anaesthesiology, 2021
- Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trialDigestive and Liver Disease, 2021
- A History of Flexible Gastrointestinal EndoscopySurgical Clinics of North America, 2020
- The synergistic effect of dexmedetomidine on propofol for paediatric deep sedationEuropean Journal of Anaesthesiology, 2020
- The effectiveness of a low-dose esketamine versus an alfentanil adjunct to propofol sedation during endoscopic retrograde cholangiopancreatographyEuropean Journal of Anaesthesiology, 2020
- Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During BronchoscopyChest, 2019
- A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopyGastrointestinal Endoscopy, 2018
- A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopyGastrointestinal Endoscopy, 2016
- A Phase IIa, Randomized, Double-Blind Study of Remimazolam (CNS 7056) Versus Midazolam for Sedation in Upper Gastrointestinal EndoscopyAnesthesia & Analgesia, 2015